Equity Profile

BEAM

Beam Therapeutics Inc.

Health CareBiotechnology$2.8B

Mar14Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and operational efficiency this quarter.

N/A

Revenue

Revenue figures will provide insight into the demand for Beam's therapies and overall business growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. With a market cap of $3 billion, it operates in the health care sector, aiming to address genetic diseases through innovative therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing expectations, which led to a 2.69% decline in stock price the following day. The company continues to focus on advancing its pipeline of genetic therapies.

Management Promises & Guidance

Commitment to furthering clinical trials for its lead programs.
Focus on strategic partnerships to enhance research capabilities.
Plans to provide more detailed updates on pipeline progress.

Expectations

Wall Street Expectations

Overall expectations for Beam's upcoming earnings are mixed, with uncertainty surrounding its clinical trial outcomes and financial performance. Investors are keenly watching for any signs of progress or setbacks.

Bull Case

The optimistic view hinges on positive updates from clinical trials, which could lead to increased investor confidence and stock price appreciation.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in its clinical programs, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest results from ongoing clinical trials?

The outcomes of these trials will be critical in determining the future success of Beam's therapies and can significantly influence investor sentiment.

What is the company's current cash runway and funding strategy?

Understanding the financial health and funding plans will help investors gauge the sustainability of operations and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of positive trial results, which could significantly boost Beam's stock price despite current bearish sentiment.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with the actual results.

Beam's recent history of beating EPS estimates suggests potential for positive surprises.

The company has a strong pipeline that could yield breakthroughs, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a significant revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Beam's clinical developments and financial health, which are pivotal for its future growth.

Bull Confirmed If

Positive clinical trial results that demonstrate efficacy could lead to a substantial increase in stock price.

Bear Confirmed If

Worse-than-expected financial results or negative trial outcomes could confirm bearish sentiment and lead to a stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with strong clinical trial results, history suggests the stock could rise by about 2.09%, confirming a bullish outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential decline of around 7.50%, which could trigger further concerns about its pipeline.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and any preliminary results.
2Details on the company's cash position and plans for future funding.
3Any new partnerships or collaborations that could enhance research capabilities.
4Management's outlook on market conditions and competitive landscape.
5Insights into the timeline for upcoming product launches or regulatory submissions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

GitLab Inc.

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and operational efficiency this quarter.

N/A

Revenue

Revenue figures will provide insight into the demand for Beam's therapies and overall business growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

Management Promises & Guidance

Commitment to furthering clinical trials for its lead programs.
Focus on strategic partnerships to enhance research capabilities.
Plans to provide more detailed updates on pipeline progress.

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on positive updates from clinical trials, which could lead to increased investor confidence and stock price appreciation.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in its clinical programs, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest results from ongoing clinical trials?

The outcomes of these trials will be critical in determining the future success of Beam's therapies and can significantly influence investor sentiment.

What is the company's current cash runway and funding strategy?

Understanding the financial health and funding plans will help investors gauge the sustainability of operations and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential impact of positive trial results, which could significantly boost Beam's stock price despite current bearish sentiment.

Supporting Evidence

The options market is pricing a 10.21% move, indicating expectations of volatility that may not align with the actual results.

Beam's recent history of beating EPS estimates suggests potential for positive surprises.

The company has a strong pipeline that could yield breakthroughs, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a significant revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Beam's clinical developments and financial health, which are pivotal for its future growth.

Bull Confirmed If

Positive clinical trial results that demonstrate efficacy could lead to a substantial increase in stock price.

Bear Confirmed If

Worse-than-expected financial results or negative trial outcomes could confirm bearish sentiment and lead to a stock decline.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations with strong clinical trial results, history suggests the stock could rise by about 2.09%, confirming a bullish outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess future growth.

Miss

Should the company miss expectations, history suggests a potential decline of around 7.50%, which could trigger further concerns about its pipeline.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials and any preliminary results.
2Details on the company's cash position and plans for future funding.
3Any new partnerships or collaborations that could enhance research capabilities.
4Management's outlook on market conditions and competitive landscape.
5Insights into the timeline for upcoming product launches or regulatory submissions.